Applicants have prepared this amendment to direct the insertion of the "Sequence Listing" into the specification.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Early and favorable consideration is requested.

Respectfully submitted,

Royal N. Ronning, Jr. 32,829
Attorney for Applicants

Amersham Biosciences Corp.
800 Centennial Avenue
P. O. Box 1327
Piscataway, NJ 08855-1327

Tel: (732) 457-8423
Fax: (732) 457-8463

H:\DEPT\Law_Dept\IP Dept\Amendments\Second Preliminary Amendment-PA9816 (3-26-02).doc

SEQUENCE LISTING

<110>   Storey, Anthony E
        Mendizabal, Marivi
        Champion, Susan
        Gibson, Alex
        Guilbert, Benedicte
        Wilson, Ian A
        Knox, Peter

<120>   Labelled Glutamine and Lysine Analogues

<130>   PA-9816

<140>   09/674,616
<141>   1999-05-14

<150>   PCT/GB99/01550
<151>   1999-05-14

<150>   EP 98303872.0
<151>   1998-05-15

<160>   29

<170>   PatentIn version 3.1

<210>   1
<211>   12
<212>   PRT
<213>   synthetic peptide

<400>   1

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys
1   5   10

<210>   2
<211>   13
<212>   PRT
<213>   synthetic peptide

<400>   2

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1   5   10

```
<210>  3
<211>  13
<212>  PRT
<213>  synthetic peptide

<400>  3

Asn Gln Glu Ala Val Ser Pro Tyr Thr Leu Leu Lys Gly
1               5                   10


<210>  4
<211>  13
<212>  PRT
<213>  synthetic peptide

<400>  4

Asn Ala Glu Ala Val Ser Pro Tyr Thr Leu Leu Lys Gly
1               5                   10


<210>  5
<211>  13
<212>  PRT
<213>  synthetic peptide

<400>  5

Asn Gln Gln Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1               5                   10


<210>  6
<211>  3
<212>  PRT
<213>  synthetic peptide

<400>  6

Asn Gln Gly
1


<210>  7
<211>  6
<212>  PRT
```

<213>   synthetic peptide

<400>   7

Asn Gln Glu Gln Val Gly
1   5

<210>   8
<211>   9
<212>   PRT
<213>   synthetic peptide

<400>   8

Asn Gln Glu Gln Val Ser Pro Tyr Gly
1   5

<210>   9
<211>   13
<212>   PRT
<213>   synthetic peptide

<400>   9

Asn Gln Glu Gln Val Ser Pro Leu Thr Leu Leu Lys Gly
1   5   10

<210>   10
<211>   13
<212>   PRT
<213>   synthetic peptide

<220>
<221>   MISC_FEATURE
<222>   (8)..(8)
<223>   MISC_FEATURE "Xaa" = 2-napthylalanine

<400>   10

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1   5   10

<210>   11

```
<211>  13
<212>  PRT
<213>  synthetic peptide

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  MISC_FEATURE "Xaa" = pBr-Phe


<400>  11

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1               5                   10


<210>  12
<211>  13
<212>  PRT
<213>  synthetic peptide

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  MISC_FEATURE "Xaa" = I-Tyr


<400>  12

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1               5                   10


<210>  13
<211>  13
<212>  PRT
<213>  synthetic peptide

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  MISC_FEATURE "Xaa" = I2-Tyr


<400>  13

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1               5                   10
```

```
<210>   14
<211>   13
<212>   PRT
<213>   synthetic peptide

<220>
<221>   MISC_FEATURE
<222>   (12)..(12)
<223>   MISC_FEATURE "Xaa" = D-Lys


<400>   14

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Xaa Gly
1                   5                   10


<210>   15
<211>   13
<212>   PRT
<213>   synthetic peptide

<220>
<221>   MISC_FEATURE
<222>   (8)..(8)
<223>   MISC_FEATURE "Xaa" = D-Tyr


<220>
<221>   MISC_FEATURE
<222>   (12)..(12)
<223>   MISC_FEATURE "Xaa" = D-Lys


<400>   15

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
1                   5                   10


<210>   16
<211>   13
<212>   PRT
<213>   synthetic peptide

<220>
```

<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = D-Ser

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> MISC_FEATURE "Xaa" = D-Lys

<400> 16

Asn Gln Glu Gln Val Xaa Pro Xaa Thr Leu Leu Xaa Gly
1   5   10

<210> 17
<211> 13
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> MISC_FEATURE"Xaa" = D-Val

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = D-Ser

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE

<222> (12)..(12)
<223> MISC_FEATURE "Xaa" = D-Lys

<400> 17

Asn Gln Glu Gln Xaa Xaa Pro Xaa Thr Leu Leu Xaa Gly
1   5   10

<210> 18
<211> 13
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> MISC_FEATURE "Xaa" = D-Asn

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> MISC_FEATURE "Xaa" = D-Lys

<400> 18

Xaa Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
1   5   10

<210> 19
<211> 13
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

```
<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  MISC_FEATURE "Xaa" = beta-Ala


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  MISC_FEATURE "Xaa" = D-Lys


<400>  19

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Xaa
1               5                   10


<210>  20
<211>  12
<212>  PRT
<213>  synthetic peptide

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  MISC_FEATURE "Xaa" = D-Tyr


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  MISC_FEATURE "Xaa" = D-Lys


<400>  20

Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Xaa Gly
1               5                   10


<210>  21
<211>  13
<212>  PRT
<213>  synthetic peptide
```

<220>
<221> MISC_FEATURE
<222> (5)..(12)
<223> MISC_FEATURE = D-amino acids

<400> 21

Asn Gln Glu Gln Val Ser Pro Tyr Thr Leu Leu Lys Gly
1   5   10

<210> 22
<211> 9
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (2)..(9)
<223> MISC_FEATURE = D-amino acids

<400> 22

Gly Lys Leu Leu Thr Tyr Pro Ser Val
1   5

<210> 23
<211> 9
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> MISC_FEATURE "Xaa" = D-Val

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = O-methyl serine

<400> 23

Asn Gln Gln Gln Xaa Xaa Pro Leu Gly
1   5

<210>   24
<211>   13
<212>   PRT
<213>   synthetic peptide

<400>   24

Asn Gln Glu Gln Val Ser Pro Tyr Ala Ala Ala Ala Gly
1   5   10

<210>   25
<211>   10
<212>   PRT
<213>   synthetic peptide

<400>   25

Leu Gly Pro Gly Gln Ser Lys Val Ile Gly
1   5   10

<210>   26
<211>   6
<212>   PRT
<213>   synthetic peptide

<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   MISC_FEATURE "Xaa" = pyro-Glu

<400>   26

Xaa Ala Gln Ile Val Gly
1   5

<210>   27
<211>   12
<212>   PRT
<213>   synthetic peptide

<400> 27

Leu Glu Phe Asp Thr Gln Ser Lys Asn Ile Leu Gly
1   5   10

<210> 28
<211> 7
<212> PRT
<213> synthetic peptide

<400> 28

Gly Gln Asp Pro Val Lys Gly
1   5

<210> 29
<211> 12
<212> PRT
<213> synthetic peptide

<400> 29

Tyr Glu Val His His Gln Lys Leu Val Phe Phe Gly
1   5   10